E2F3和AR在前列腺癌组织中的表达及意义

摘要

目的:检测E2F3、AR在前列腺组织中的表达水平,分析两者的表达与前列腺癌病理分级和临床分期的关系.方法:利用免疫组织化学方法检测50例前列腺癌组织、50例良性前列腺增生组织中E2F3、AR蛋白的表达；采用SPSS 13.0进行统计学处理.结果:E2F3在良性前列腺增生组织、前列腺癌组织中的阳性表达率分别为20.00％( 10/50)及66.00％(33/50),差异有统计学意义(P＜0.05),且在前列腺癌组织中的表达与肿瘤临床分期和病理恶性程度呈正相关(rs分别为0.471和0.329,P＜0.05).前列腺癌组织中AR表达水平低于良性前列腺增生组织(P＜0.05),且在前列腺癌组织中的表达与肿瘤临床分期和病理恶性程度呈负相关(rs分别为-0.403和-0.391,均P＜0.01).E2F3在前列腺癌组织中的表达与AR在前列腺癌组织中的表达无相关关系(rs=-0.017,P＞0.05).结论:E2F3在前列腺癌的发生、发展中起着重要作用.%Objective: To investigate expression levels of E2F3 and AR in prostate cancer (Pca) and discuss their relationship with the clinical stage and pathologic grade. Methods: The expressions of E2F3 and AR were detected by immuno-histochemistry (IHC) in tissues from 50 cases of prostate cancer and 50 cases benign prostatic hyperplasia (BPH). The relationship between expressions of E2F3 and AR with the clinical stage and pathologic grade was analyzed by SPSS 13.0. Re-Sults: The positive rate of E2F3 was 20% (2/10) and 66% (33/50) for BPH and prostate cancer respectively. The expression level of E2F3 was higher in prostate cancer than that in BPH (P < 0.05). There was a positive correlation in expression of E2F3 between the clinical stage and pathological grade (r.= 0.471 and 0.329, P < 0.05 and P < 0.01). The expression of AR was lower in Pca than that of BPH (P < 0.05). The expression of AR in Pca was negatively correlated with the clinical stage and pathological grade (rs = -0.403 and -0.391 ,P < 0.01). There was no correlation between the expression of E2F3 and the expression of AR in Pca(rs = -0.017, P > 0.05). Conclusion: E2F3 may play an important role in the onset and progression of prostate cancer.